Evidence map›Paper›PMID 28928129›Full record

ArticleCancer research2017

New Advances and Challenges of Targeting Cancer Stem Cells.

Nurmaa K Dashzeveg, Rokana Taftaf, Erika K Ramos, Luke Torre-Healy, Anastasia Chumakova, Daniel J Silver, Tyler J Alban, Maksim Sinyuk, Praveena S Thiagarajan, Awad M Jarrar and 8 more

Abstract read
In one paragraph

Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Cancer stem cell mobilization and therapeutic targeting of the 5T4 oncofetal antigen.Therapeutic advances in vaccines and immunotherapy · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Nurmaa K DashzevegDepartment of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Rokana TaftafDepartment of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Erika K RamosDepartment of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Luke Torre-HealyDepartment of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
Anastasia ChumakovaDepartment of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
Daniel J SilverDepartment of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
Tyler J AlbanDepartment of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
Maksim SinyukDepartment of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
Praveena S ThiagarajanDepartment of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
Awad M JarrarDepartment of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
Soumya M TuragaDepartment of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
Caner SayginDepartment of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
Erin Mulkearns-HubertDepartment of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
Masahiro HitomiDepartment of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
Jeremy N RichDepartment of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
Stanton L GersonThe Case Comprehensive Cancer Center, Cleveland, Ohio.
Justin D LathiaDepartment of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
Huiping LiuDepartment of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. huiping.liu@northwestern.edu.

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
CARCINOGENESIS TRAINING PROGRAMT32CA009560 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Kathleen Janee Green · 1986 to 2026
$8.4M
RESEARCH ONCOLOGY TRAINING GRANTT32CA059366 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JACKSON, MARK W. · 1993 to 2025
$5.5M
Identifying a network of miRNAs and genes that regulate breast tumor metastasisR00CA160638 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LIU, HUIPING · 2014 to 2017
$883k
Serotonin drives cancer stem cell maintenance and glioblastoma progressionF32CA213727 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI SILVER, DANIEL J · 2017 to 2018
$94k
Cancer Stem Cell (CSC) 2016 ConferenceR13CA206377 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 2016 to 2016
$5k
NCI NIH HHS F32 CA213727NCI NIH HHS P30 CA043703NCI NIH HHS R00 CA160638NCI NIH HHS R13 CA206377NCI NIH HHS T32 CA009560NCI NIH HHS T32 CA059366
6 · The paper itself

Abstract

The second International Cancer Stem Cell Conference in Cleveland, Ohio, on September 20-23, 2016, convened 330 attendees from academic, industrial, and clinical organizations. It featured a debate on the concepts and challenges of the cancer stem cells (CSC) as well as CSC-centered scientific sessions on clinical trials, genetics and epigenetics, tumor microenvironment, immune suppression, metastasis, therapeutic resistance, and emerging novel concepts. The conference hosted 35 renowned speakers, 100 posters, 20 short talks, and a preconference workshop. The reported advances of CSC research and therapies fostered new collaborations across national and international borders, and inspired the next generation's young scientists.

Indexed as

AnimalsAntineoplastic AgentsDrug Resistance, NeoplasmEpigenesis, GeneticHumansNeoplasmsNeoplastic Stem CellsTumor MicroenvironmentAntineoplastic Agents

Identifiers

PMID28928129
PMCPMC5833988

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.